January 2025 kicked off with a wave of impactful biotech deals, setting the stage for an exciting year of innovation.

In this video, Sham Mailankody, MBBS discusses the current state of the pipeline for developing multiple myeloma treatments.

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinic ...

Under terms of the deal, AbbVie will provide Neomorph with an upfront payment and the potential to earn up to $1.64 billion ...

AbbVie ABBV announced that it has entered into a collaboration and option-to-license agreement with the San Diego-based ...

NKCEs offer a significant advancement over conventional monoclonal antibodies (mAbs) by enhancing Antibody-Dependent Cellular Cytotoxicity (ADCC). They achieve this by stably and selectively binding ...

Bispecific antibodies represent an innovative paradigm in cancer therapy, offering broader therapeutic potential compared to conventional monoclonal antibodies. To increase tumor selectivity while ...

Sjögren’s antibody testing is done using a blood sample. It checks antibody levels, including anti-SS-A (also called anti-Ro) and anti-SS-B (also called anti-La). Anti-SS-A and anti-SS-B are ...